Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Michael L. Greenberg"'
Autor:
Kent J. Weinhold, George M. Shaw, Xiaoying Shen, Julie M. Decker, Barton F. Haynes, Georgia D. Tomaras, Brandon F. Keele, William A. Blattner, David C. Montefiori, Robert Parks, Feng Gao, Michael L. Greenberg, Beatrice H. Hahn, Jennifer L. Kirchherr, Charles B. Hicks
Publikováno v:
Journal of Virology. 83:3617-3625
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly conserved human immunodeficiency virus type 1 (HIV-1) envelope membrane proximal external region (MPER), are among the MAbs with the broadest heterolo
Autor:
Joseph C. Gathe, Andrew R. Zolopa, Michael S. Gottlieb, Edwin DeJesus, Michael L. Greenberg, Carol Jean Guittari
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:4315-4319
Enfuvirtide is the first fusion and entry inhibitor approved for use for the treatment of human immunodeficiency virus (HIV) type 1 infection and as such represents a novel class of agents. For the population of patients experienced with three antire
Publikováno v:
Clinical Genetics. 15:327-331
We have identified trisomy 13 in two additional patients with hematologic malignancies involving the hematopoietic stem cell: a 75–year–old female with acute myelocytic leukemia and a 64–year–old female with agnogenic myelofibrosis and myeloi
Autor:
Thomas J. Matthews, Michael L. Greenberg, Karen L. Wilson, Nicolai A. Tvermoes, Jennifer E. Seedorff, John Dwyer, Mary K. Delmedico, Stephen A. Wring, Stephanie Freel, Donna K. Davison
Publikováno v:
Proceedings of the National Academy of Sciences
Enfuvirtide (ENF), the first approved fusion inhibitor (FI) for HIV, is a 36-aa peptide that acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fus
Autor:
Tom Melby, Prakash R. Sista, N. Roberts, Gabrielle Heilek-Snyder, T J Matthews, T. Kirkland, Michael L. Greenberg, Ralph DeMasi, Miklos Salgo, Nick Cammack
Publikováno v:
AIDS Research and Human Retroviruses. 22:375-385
Enfuvirtide (T-20) is the first entry inhibitor approved for treatment of HIV infection and acts by inhibiting conformational changes in the viral envelope protein gp41 that are necessary for fusion of the virus and host cell membranes. Here we prese
Publikováno v:
Future Virology. 1:79-88
HIV-1 can escape from neutralizing antibodies rapidly during natural infection. Evolution of antibody escape is an important consideration for both vaccine and therapeutic development. Recent studies highlight both the potential strength of specific
Autor:
S. Janumpalli, T J Matthews, Tom Melby, S. M. Mosier, J. Erickson, D. Lambert, D. Davison, Miklos Salgo, S. A. Stanfield-Oakley, Nick Cammack, M. Mink, Prakash Sista, Lei Jin, Michael L. Greenberg
Publikováno v:
Journal of Virology. 79:12447-12454
Enfuvirtide (ENF), a novel human immunodeficiency virus type 1 (HIV-1) fusion inhibitor, has potent antiviral activity against HIV-1 both in vitro and in vivo. Resistance to ENF observed after in vitro passaging was associated with changes in a three
Autor:
Mike Mink, Thomas J. Matthews, Donna K. Davison, Sarah M. Mosier, Ralph DeMasi, Lei Jin, Prakash Sista, Emily L. Nelson, Nick Cammack, Miklos Salgo, Michael L. Greenberg, Tom Melby
Publikováno v:
AIDS. 18:1787-1794
Enfuvirtide (ENF) is the first of a novel class of drugs that block HIV gp41-mediated viral fusion to host cells. Viruses with mutations at positions 36-38 in HIV-1 gp41 and/or reduced susceptibility to ENF have been selected both in vitro and in viv
Autor:
William A. Blattner, Trevor L. Hoffman, Lori E. Fantry, Courtenay Bartholomew, Jeffrey G. Edwards, Janet Ottinger, Kent J. Weinhold, Noreen Jack, James F. Demarest, Farley R. Cleghorn, Bisram Mahabir, Michael L. Greenberg, Thomas R. O'Brien, Kai Cao
Publikováno v:
AIDS Research and Human Retroviruses. 17:1333-1344
The immunologic and virologic factors that impact on the rate of disease progression after acute infection with human immunodeficiency virus (HIV) type 1 are poorly understood. A patient with an extraordinarily rapid disease course leading to AIDS-as
Autor:
Bryan R. Cullen, R. Ian Cumming, Michael L. Greenberg, Kenzo Tokunaga, H. Kim Lyerly, Michael A. Morse
Publikováno v:
Journal of Virology. 75:6776-6785
Laboratory isolates of human immunodeficiency virus type 1 (HIV-1) that utilize CXCR4 as a coreceptor infect primary human macrophages inefficiently even though these express a low but detectable level of cell surface CXCR4. In contrast, infection of